Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VRAYLAR vs ANTEPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Schizophrenia,Acute treatment of manic or mixed episodes associated with bipolar I disorder,Depressive episodes associated with bipolar I disorder (bipolar depression)
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
The terminal elimination half-life of cariprazine is 2-4 days, and for its active metabolites (desmethylcariprazine and didesmethylcariprazine) it is 1-3 weeks. This long half-life results in steady-state concentrations being reached after 3-4 weeks of daily dosing, contributing to prolonged clinical effects and a need for slow titration.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Active metabolites include didesmethylcariprazine (DDCAR) and desmethylcariprazine (DCAR).
Partially metabolized in the liver; some metabolites are excreted unchanged.
Cariprazine and its active metabolites are primarily eliminated via hepatic metabolism and subsequent biliary/fecal excretion. Approximately 20% of the dose is recovered in urine, mainly as inactive metabolites, while about 80% is recovered in feces, largely as unchanged cariprazine and its active metabolites.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Cariprazine is 91-97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
The apparent volume of distribution (Vd/F) is approximately 8.3 L/kg, indicating extensive tissue distribution and high lipophilicity.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Absolute oral bioavailability is not determined; however, after oral administration, peak plasma concentrations occur within 3-6 hours. Food does not significantly affect the extent of absorption.
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1.5 mg daily; maximum 3 mg/day. Child-Pugh Class C: Not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Safety and efficacy not established in pediatric patients under 18 years; not recommended.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
Elderly patients may have lower clearance; use lowest effective dose (1.5 mg daily) and titrate slowly. Not approved for dementia-related psychosis due to increased mortality risk.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
None.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse reactions in elderly patients with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Leukopenia, neutropenia, and agranulocytosis,Orthostatic hypotension and syncope,Falls,Seizures,Body temperature dysregulation,Dysphagia,Cognitive and motor impairment
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Known hypersensitivity to cariprazine or any components of the formulation
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
No specific food restrictions. Vraylar can be taken with or without food. Grapefruit and grapefruit juice do not significantly interact with Vraylar. High-fat meals do not affect absorption.
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following late third trimester exposure. Vraylar (cariprazine) is classified as Pregnancy Category C; no adequate human studies.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Excretion into human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, discontinue drug or nursing, considering importance of drug to mother.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
No established dosing adjustments for pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure. Use lowest effective dose and monitor clinical response and tolerability. Clinical pharmacokinetic data not available; consider empiric dose adjustment based on tolerability.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
Vraylar (cariprazine) requires dose adjustment in moderate hepatic impairment (Child-Pugh B): maximum dose 3 mg/day. Avoid in severe hepatic impairment (Child-Pugh C). Titrate slowly to minimize akathisia risk. For acute mania, start at 1.5 mg/day on day 1, increase to 3 mg/day on day 2. For schizophrenia, start at 1.5 mg/day, may increase to 3 mg/day after 2 days, then further in 1.5 mg increments weekly. For bipolar depression, target dose is 1.5-3 mg/day; start at 1.5 mg/day, increase to 3 mg/day after 2 days if needed. Monitor for extrapyramidal symptoms, especially akathisia which is dose-dependent. Renal impairment: no dose adjustment needed. CYP3A4 inducers (e.g., rifampin) decrease exposure; may need dose increase. CYP3A4 inhibitors (e.g., ketoconazole) increase exposure; reduce dose.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Take Vraylar once daily with or without food. Swallow capsules whole; do not crush or chew.,Do not abruptly stop taking Vraylar without talking to your doctor; sudden discontinuation may cause withdrawal symptoms such as nausea, vomiting, or trouble sleeping.,Avoid alcohol and illicit drugs while taking Vraylar, as they can worsen side effects like dizziness or drowsiness.,You may experience restlessness or an urge to move (akathisia), especially during dose increases; tell your doctor if this occurs.,Vraylar may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how the medication affects you.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double up.,Contact your doctor immediately if you experience uncontrolled muscle movements, especially of the face or tongue, or signs of neuroleptic malignant syndrome (fever, muscle rigidity, confusion).,Store at room temperature 20-25°C (68-77°F), away from moisture and heat.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VRAYLAR vs ANTEPAR, answered by our medical review team.
VRAYLAR is a Atypical Antipsychotic that works by Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.. ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VRAYLAR and ANTEPAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VRAYLAR is: 1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.. The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VRAYLAR and ANTEPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VRAYLAR is classified as Category C. First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following l. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.